iWel

Executive Summary

iWel Health Inc. is a US-based digital health company developing an affordable, over-the-counter continuous glucose monitoring (CGM) biosensing platform. Founded in 2016 and headquartered in San Francisco, the company targets the wellness and metabolic health market, including weight loss, prediabetes, and Type 2 diabetes management. Its technology is also being explored for broader applications in digital therapeutics and pet healthcare. By focusing on an OTC model, iWel aims to lower the cost barrier and expand CGM access beyond traditional diabetic populations into the growing metabolic health and wellness segments. The company operates in the highly competitive CGM space, but its differentiated value proposition lies in affordability and over-the-counter availability, which could unlock large addressable markets in preventive health and direct-to-consumer channels.

Upcoming Catalysts (preview)

• Q2 2027FDA Clearance for OTC CGM Device60% success
• Q4 2026Strategic Partnership with a Major Digital Health Platform40% success
• Q3 2027Launch of Pet Healthcare CGM Application30% success